Sherene Loi’s Post

Did you know breast cancer is the most common form of disease worldwide? While there are preventative tests for women and men to capture signs of breast cancer early, for some, it still can be too late. This new "ultra-sensitive" blood test is truly groundbreaking in that regard - helping to predict if breast cancer will return years before the disease shows up on scans, allowing treatment to start earlier and improve survival rates. While the journey to widespread availability may be complex, the implications of this advancement are profound. I eagerly anticipate the day when this test becomes a standard tool in the fight against breast cancer, offering hope and improved outcomes globally. #BreastCancer #BloodTest #ResearchBreakthrough

🥼💉Great Article: 5 New advancements in the lung #cancer field 🧬Lung cancer survival rates depend on diagnosis stage, with over 55% of stage 1 patients surviving for five years or more in England. There are two main types: small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC is more aggressive and often caused by smoking, while NSCLC is the most common, accounting for 80% of cases. This article explores the current clinical trials and research focused on improving treatments and early diagnosis for both types. #research #stage #cancerresearch #pharma https://lnkd.in/dpKysRbb

Analysis of Breast Cancer Mortality in the US—1975 to 2019 Findings: Improvements in treatment and screening after 1975 were associated with a 58% reduction in breast cancer mortality in 2019, from an estimated 64 deaths without intervention to 27 per 100 000 women (age adjusted). Approximately 29% of this reduction was associated with treating metastatic breast cancer, 25% with screening, and 47% with treating stage I to III breast cancer. https://lnkd.in/gcmsJSNr #breast #cancer #mortality #analysis #findings

First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study. What's new? Non-small cell lung cancer (NSCLC) patients often are diagnosed in advanced stages of disease, at which point, in cases without targetable mutations, first-line therapy typically entails platinum-based chemotherapy. A recommended therapy is albumin-bound paclitaxel plus carboplatin combination (nab-P/C). Here, the authors evaluated the use of first-line nab-P/C therapy in a real-world setting in patients with locally advanced or metastatic NSCLC. Results show that survival was improved among nab-P/C-treated patients, with better outcomes observed particularly among patients age 70 and older and in those with mild to moderate renal impairment. Improvements in tumor response, independent of histological subtype, were also observed. Dechow T, Riera-Knorrenschild J, Hackanson B, Janssen J, Schulz H, Oppermann U, Chiabudini M, von Weikersthal LF, Budweiser S, Nacke A, Taeuscher D, Welslau M, Potthoff K. Int J Cancer. 2023 Jul 1;153(1):141-152. doi: 10.1002/ijc.34467. Epub 2023 Mar 8. https://bit.ly/3uLTeGp Picture with courtesy of the National Cancer Institute

METASTATIC BREAST CANCER AWARENESS DAY | OCTOBER 13 On October 13th, National Metastatic Breast Cancer Awareness Day focuses on the estimated 271,270 Americans diagnosed with this destructive cancer. #MetastaticBreastCancerAwarenessDay Each year, treatments for all kinds of breast cancer are improving. Metastatic cancer is a stage IV cancer invading all areas of the body. It affects the liver, lungs, brain, lymph nodes, and more. Both men and women are diagnosed each year. Additionally, there are different types of metastatic breast cancer. https://lnkd.in/gqVDW9qx

There’s a lot going on in Advanced Breast Cancer. We report on discussions at #ABCLisbon, where specialists, patients and advocates gathered to make sense of it all and update guidelines on standards of care and best practice. Read the full article by anna wagstaff on Cancerworld ⤵ https://lnkd.in/dmiYWpCF ABC Global Alliance #ABC7 #BreastCancer

In honor of #NationalCancerResearchMonth, BCRF investigator Dr. Sherene Loi spoke with BCRF's Sadia Zapp about global collaboration, recurrence risk reduction, strategies to better treat younger patients, and what she envisions for the future of breast cancer research. Through the landmark BCRF-supported SOFT trial, Dr. Loi and her colleagues have already developed treatment strategies that have improved outcomes for women under 40, and she recently published notable research on TILs in triple-negative breast cancer. Find the full conversation below. https://bit.ly/4dQFITA"

A forum to discuss the most recent developments in oncology care: 8th Cancer World Congress 2024, Dubrovnik, Croatia https://lnkd.in/gRG9ZZWb #cancer #breastcancer #lungcancer #cancerresearch #cancerconference #cwc2024 #cancerawareness #cancercare #cancersupport #cancerprevention #CancerWorldCongress #earlybirdregistration #OncoDaily #Croatia #CancerResearch #CancerDiagnostics #CancersMDPI #MDPI #CancerNews #oncology #cancerconferences #oncologyconference #cwc2024 #prostatecancer #croatia #lungcancer #cancergenetics #coloncancer #prostatecancer #skincancer #pancreaticcancer #thyroidcancer #oralcancer #cancerworldcongress #cancerconference2024 #Oncologysymposiums #oncologymeetings #Cancerseminars #Cancertherapyevents #conferences #earlybird

Lung cancer is the leading cause of cancer-related deaths globally. Early detection is crucial, as it significantly improves survival rates. However, in the United States, the utilization of CT scans for lung cancer screening is low, with only a 5.8% adoption rate. There is a growing need for accessible and simple diagnostic methods, like blood tests, to detect lung cancer in its early stages. Such advancements could enhance compliance with lung cancer screening protocols, ultimately saving lives and improving the quality of life for survivors.#earlydetection #lungcancerawareness #lungcancerscreening